Last reviewed · How we verify
Fast-acting insulin aspart
Fast-acting insulin aspart, marketed by Aristotle University of Thessaloniki, holds a significant position in the diabetes management market. The key composition patent, set to expire in 2028, provides a strong barrier to generic competition. However, the lack of detailed revenue data and primary trial results poses a risk in assessing its full market potential and efficacy compared to competitors.
At a glance
| Generic name | Fast-acting insulin aspart |
|---|---|
| Also known as | Fiasp® |
| Sponsor | Aristotle University Of Thessaloniki |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (NA)
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor
- Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers (PHASE2, PHASE3)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
- A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice
- A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fast-acting insulin aspart CI brief — competitive landscape report
- Fast-acting insulin aspart updates RSS · CI watch RSS
- Aristotle University Of Thessaloniki portfolio CI